RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer.
Seth S, Matsui Y, Fosnaugh K, Liu Y, Vaish N, Adami R, Harvie P, Johns R, Severson G, Brown T, Takagi A, Bell S, Chen Y, Chen F, Zhu T, Fam R, Maciagiewicz I, Kwang E, McCutcheon M, Farber K, Charmley P, Houston ME Jr, So A, Templin MV, Polisky B.
Seth S, et al. Among authors: houston me jr.
Mol Ther. 2011 May;19(5):928-35. doi: 10.1038/mt.2011.21. Epub 2011 Mar 1.
Mol Ther. 2011.
PMID: 21364537
Free PMC article.